← Back to patent-cliff list
CAS 851591-06-5
(1S,2S,3R,4S,7R,9S,10R,11R,12R,15S)-4-(acetyloxy)-1,11,15-trihydroxy-10,14,17,17-tetramethyl-9,12-bis[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate
Codes: (III)140605-9-a
Application context (from source-drug indications)
Bladder cancerDocetaxel polymeric micelle (Samyang Biopharmaceuticals)Head and neck cancerDocetaxel polymeric micelle (Samyang Biopharmaceuticals)Head and neck squamous cell carcinomaDocetaxel polymeric micelle (Samyang Biopharmaceuticals)Solid tumourDocetaxel polymeric micelle (Samyang Biopharmaceuticals)Non-small cell lung cancerDocetaxel （Beihai）Prostate cancerDocetaxel （Beihai）Castration-resistant prostate cancerDocetaxel （Beihai）Breast cancerDocetaxel （Beihai）Head and neck cancerDocetaxel （Beihai）Head and neck squamous cell carcinomaDocetaxel （Beihai）
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Docetaxel polymeric micelle (Samyang Biopharmaceuticals) | Tier C — Watch / trade | - |
| Docetaxel （Beihai） | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
13-Acetyl-9-dihydrobaccatin-III→(2alpha,5beta,7beta,9beta,10beta,13alpha)-4-(Acetyloxy)-1,7,9,10,13-pentahydroxy-5,20-epoxytax-11-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10R,11R,12R,15S)-4-(acetyloxy)-1,11,15-trihydroxy-10,14,17,17-tetramethyl-9,12-bis[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(4S,5R)-3-[(tert-butoxy)carbonyl]-4-phenyl-1,3-oxazolidine-5-carboxylic acid→5-(1S,2S,3R,4S,7R,9S,10R,11R,12R,15S)-4-(acetyloxy)-2-(benzoyloxy)-1,11-dihydroxy-10,14,17,17-tetramethyl-9,12-bis[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-15-yl 3-tert-butyl (4S,5R)-4-phenyl-1,3-oxazolidine-3,5-dicarboxylate→5-(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-2-(benzoyloxy)-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-9,12-bis[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-15-yl 3-tert-butyl (4S,5R)-4-phenyl-1,3-oxazolidine-3,5-dicarboxylate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(Acetyloxy)-15-[[(2R,3S)-3-amino-2-hydroxy-3-phenylpropanoyl]oxy]-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate
13-Acetyl-9-dihydrobaccatin-III→(2alpha,5beta,7beta,9beta,10beta,13alpha)-4-(Acetyloxy)-1,7,9,10,13-pentahydroxy-5,20-epoxytax-11-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10R,11R,12R,15S)-4-(acetyloxy)-1,11,15-trihydroxy-10,14,17,17-tetramethyl-9,12-bis[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(4S,5R)-3-[(tert-butoxy)carbonyl]-4-phenyl-1,3-oxazolidine-5-carboxylic acid→5-(1S,2S,3R,4S,7R,9S,10R,11R,12R,15S)-4-(acetyloxy)-2-(benzoyloxy)-1,11-dihydroxy-10,14,17,17-tetramethyl-9,12-bis[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-15-yl 3-tert-butyl (4S,5R)-4-phenyl-1,3-oxazolidine-3,5-dicarboxylate→5-(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-2-(benzoyloxy)-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-9,12-bis[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-15-yl 3-tert-butyl (4S,5R)-4-phenyl-1,3-oxazolidine-3,5-dicarboxylate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(Acetyloxy)-15-[[(2R,3S)-3-amino-2-hydroxy-3-phenylpropanoyl]oxy]-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.